Radiotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Radiotherapy, including details on cancer treatment, side effects.

The expanding role of rituximab and radioimmunotherapy in the treatment of B-cell lymphomas.

Jacobs SA, Foon KA

University of Pittsburgh School of Medicine, 5150 Centre Avenue, Pittsburgh, PA 15232, USA. jacobssa@upmc.edu

The role of rituximab in the treatment of B-cell lymphomas has rapidly emerged from the relapsed setting to first-line combination regimens across the broad range of histologic subtypes. The role of maintenance rituximab in indolent lymphomas after first-line therapy needs to be defined along with the integration of radioimmunotherapy into the first-line therapeutic regimens. As mechanisms of action/resistance to monoclonal antibody therapy are better understood, approaches to predicting response and optimizing combination therapy to overcoming primary and acquired resistance may be developed.

Published 26 October 2007 in Expert Opin Biol Ther, 7(11): 1749-62.
Full-text of this article is available online (may require subscription).

© 2004-2008 Radiotherapy Research Today. All Rights Reserved.